Corcept Therapeutics (NASDAQ:CORT) Issues Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Corcept Therapeutics (NASDAQ:CORT) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19), FiscalAI reports. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm had revenue of $164.90 million for the quarter, compared to analysts’ expectations of $185.83 million. During the same quarter last year, the firm posted $0.17 earnings per share. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Corcept raised 2026 revenue guidance to $950 million–$1.05 billion after reporting Q1 revenue of $164.9 million (Q1 net loss $31.8 million; cash & investments $515 million as of March 31).
• Endocrinology demand is at record levels (new prescriptions, prescribers, and patient starts), driven by the CATALYST and MOMENTUM studies that identify high hypercortisolism prevalence; management expects the Cushing’s business to grow to at least $2 billion annually by decade‑end and has an NDA for relacorilant under FDA review.
• The FDA approved Lifyorli early for platinum‑resistant ovarian cancer after ROSELLA showed a 35% reduction in risk of death (HR 0.65, p=0.0004); early launch traction (>200 prescribers), quick NCCN preferred listing, and management projects >$1 billion U.S. revenue by decade‑end.
• Phase II DASALS results for dazucorilant showed large survival benefits (84% reduction in risk of death at 1 year; 87% at 2 years, p≤0.0009) but GI tolerability caused discontinuations, and Corcept plans a 300 mg‑focused Phase III later this year with dose‑titration work to address tolerability.
• Corcept is broadening its pipeline—ongoing BELLA relacorilant combination arms, a nenocorilant + nivolumab immunotherapy program, and the MONARCH Phase II in MASH (readout by year‑end)—which could materially expand markets if forthcoming data are positive but remain uncertain until readouts.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT traded down $0.07 during midday trading on Thursday, hitting $46.52. The company’s stock had a trading volume of 1,233,033 shares, compared to its average volume of 953,595. The stock has a fifty day moving average price of $39.14 and a 200 day moving average price of $54.61. Corcept Therapeutics has a one year low of $28.66 and a one year high of $91.00. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $4.99 billion, a price-to-earnings ratio of 56.73 and a beta of 0.25.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 2 ALS survival data released — Corcept reported two‑year overall survival benefit for dazucorilant in the DAZALS Phase 2 study, which supports development of its cortisol‑modulator franchise beyond oncology and endocrinology. BusinessWire: DAZALS survival data
• Positive Sentiment: Phase 3 ROSELLA survival readout bolsters Lifyorli story — recent Phase 3 overall survival results for Lifyorli + nab‑paclitaxel in platinum‑resistant ovarian cancer keep the oncology franchise in focus as a revenue driver. InsiderMonkey: ROSELLA data
• Positive Sentiment: Company says it is guiding higher on Lifyorli‑fueled revenue growth — management highlighted commercial momentum and raised forward expectations, which could support upside if sales accelerate. TipRanks: Guidance update
• Neutral Sentiment: Revenue grew 4.9% YoY to $164.9M in Q1 2026, showing underlying topline traction despite missing estimates; management hosted a conference call and issued a press release with financial details. BusinessWire: Q1 results
• Negative Sentiment: Q1 earnings and revenue missed expectations — CORT reported a loss of $0.30/share versus a -$0.11 consensus and revenue of $164.9M vs. $185.8M expected, a material miss that pressured near‑term sentiment. MarketBeat: Earnings recap
• Negative Sentiment: Analyst and news summaries flagged the revenue miss and EPS loss as the primary reasons for the share pullback today. Zacks: Earnings coverage MSN: Revenue miss SFGate: Earnings snapshot

Analyst Ratings Changes

CORT has been the topic of several analyst reports. HC Wainwright cut their price target on shares of Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Wolfe Research raised shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. Finally, Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $77.67.

Insider Activity

In other Corcept Therapeutics news, Director G Leonard Baker, Jr. purchased 100,000 shares of the stock in a transaction dated Tuesday, March 17th. The shares were bought at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the transaction, the director directly owned 1,146,631 shares in the company, valued at approximately $37,999,351.34. This trade represents a 9.55% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Guyer sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $40.97, for a total transaction of $819,400.00. Following the completion of the sale, the insider directly owned 2,231 shares in the company, valued at approximately $91,404.07. This trade represents a 89.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 86,198 shares of company stock valued at $3,668,569 over the last quarter. Company insiders own 20.80% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds have recently bought and sold shares of CORT. Advisory Services Network LLC purchased a new position in Corcept Therapeutics during the third quarter valued at approximately $25,000. Atlas Capital Advisors Inc. purchased a new position in Corcept Therapeutics during the fourth quarter valued at approximately $31,000. Larson Financial Group LLC grew its stake in Corcept Therapeutics by 2,326.3% during the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 442 shares in the last quarter. Gould Capital LLC grew its stake in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its stake in Corcept Therapeutics by 128.5% during the third quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 433 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.